[go: up one dir, main page]

MX2018010564A - Uso de moduladores del receptor de glucocorticoides para potenciar inhibidores de puntos de regulacion. - Google Patents

Uso de moduladores del receptor de glucocorticoides para potenciar inhibidores de puntos de regulacion.

Info

Publication number
MX2018010564A
MX2018010564A MX2018010564A MX2018010564A MX2018010564A MX 2018010564 A MX2018010564 A MX 2018010564A MX 2018010564 A MX2018010564 A MX 2018010564A MX 2018010564 A MX2018010564 A MX 2018010564A MX 2018010564 A MX2018010564 A MX 2018010564A
Authority
MX
Mexico
Prior art keywords
glucocorticoid receptor
potentiate
inhibitors
receptor modulators
regulation points
Prior art date
Application number
MX2018010564A
Other languages
English (en)
Other versions
MX390517B (es
Inventor
Nt Hazel
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of MX2018010564A publication Critical patent/MX2018010564A/es
Publication of MX390517B publication Critical patent/MX390517B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Steroid Compounds (AREA)

Abstract

La presente invención proporciona un método que combina un inhibidor de puntos de regulación y un modulador del receptor de glucocorticoides para el tratamiento contra el cáncer, por ejemplo, un cáncer sensible al inhibidor de puntos de regulación.
MX2018010564A 2016-03-01 2017-02-28 Uso de moduladores del receptor de glucocorticoides para potenciar inhibidores de puntos de regulacion. MX390517B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662302106P 2016-03-01 2016-03-01
US201662320276P 2016-04-08 2016-04-08
PCT/US2017/019948 WO2017151613A1 (en) 2016-03-01 2017-02-28 The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors

Publications (2)

Publication Number Publication Date
MX2018010564A true MX2018010564A (es) 2018-11-09
MX390517B MX390517B (es) 2025-03-20

Family

ID=59744340

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018010564A MX390517B (es) 2016-03-01 2017-02-28 Uso de moduladores del receptor de glucocorticoides para potenciar inhibidores de puntos de regulacion.

Country Status (14)

Country Link
US (3) US10980797B2 (es)
EP (1) EP3423453A4 (es)
JP (4) JP6847120B2 (es)
KR (1) KR102845317B1 (es)
CN (1) CN109071537B (es)
AU (1) AU2017228329B2 (es)
CA (1) CA3015218A1 (es)
CL (1) CL2018002467A1 (es)
IL (2) IL297201A (es)
MX (1) MX390517B (es)
PH (1) PH12018501848B1 (es)
SG (1) SG11201807421TA (es)
WO (1) WO2017151613A1 (es)
ZA (1) ZA201805787B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US12226412B2 (en) 2012-05-25 2025-02-18 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
MX390517B (es) 2016-03-01 2025-03-20 Corcept Therapeutics Inc Uso de moduladores del receptor de glucocorticoides para potenciar inhibidores de puntos de regulacion.
US9943505B2 (en) * 2016-09-09 2018-04-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat pancreatic cancer
CN110520121B (zh) 2017-03-31 2023-07-04 科赛普特治疗学股份有限公司 糖皮质激素受体调节剂治疗宫颈癌
MX393313B (es) 2017-06-20 2025-03-24 Corcept Therapeutics Inc Metodos de tratamiento de tumores neuroepiteliales usando moduladores selectivos del receptor de glucocorticoide.
EP3858359B1 (en) 2018-09-28 2024-03-06 Kyungpook National University Industry-Academic Cooperation Foundation Composition, comprising a thiamine derivative, for prevention or treatment of hypercortisolemia
MX2021005438A (es) * 2018-11-09 2021-06-15 Corcept Therapeutics Inc Metodos para reducir el tama?o de tumores hipofisarios.
IL284061B2 (en) * 2018-12-19 2025-02-01 Corcept Therapeutics Inc A preparation containing a relaxant
WO2020132046A1 (en) * 2018-12-19 2020-06-25 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
PH12021552025A1 (en) 2019-02-22 2022-08-22 Corcept Therapeutics Inc Therapeutic uses of relacorilant, a heteroaryl-ketone fused azadecalin glucocorticoid receptor modulator
KR102845522B1 (ko) * 2019-10-16 2025-08-12 코어셉트 쎄라퓨틱스 인코포레이티드 선택적 글루코코르티코이드 수용체 길항제로 암 환자의 호중구 대 림프구 비율을 정상화시키는 방법
AU2021214938B2 (en) * 2020-01-29 2024-02-08 Corcept Therapeutics Incorporated Treatment of adrenocortical carcinoma with selective glucocorticoid receptor modulators (SGRMs) and antibody checkpoint inhibitors
IL294953A (en) * 2020-02-10 2022-09-01 Corcept Therapeutics Inc Methods for inducing an antitumor response using a selective glucocorticoid receptor modulator
CN115666573A (zh) * 2020-05-27 2023-01-31 科赛普特治疗学股份有限公司 糖皮质激素受体调节剂瑞拉可兰和cyp2c8底物的并行给药
KR20230016661A (ko) * 2020-05-27 2023-02-02 코어셉트 쎄라퓨틱스 인코포레이티드 글루코코르티코이드 수용체 조절제 렐라코릴란트 및 cyp2c9 기질의 병용 투여
WO2022134033A1 (en) * 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
US20250032506A1 (en) * 2021-12-03 2025-01-30 Board Of Regents, The University Of Texas System Glucocorticoid receptor blockade with mifepristone to sensitize pancreatic cancer to immunotherapy
CN119997939A (zh) 2022-10-06 2025-05-13 科赛普特治疗公司 糖皮质激素受体调节剂的制剂
WO2024092195A1 (en) 2022-10-28 2024-05-02 Corcept Therapeutics Incorporated Treatments for amyotrophic lateral sclerosis using dazucorilant

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4851345B2 (ja) 2004-01-09 2012-01-11 コーセプト セラピューティクス， インコーポレイテッド アザデカリン糖質コルチコイド受容体モジュレーター
NZ550362A (en) 2004-03-09 2010-06-25 Corcept Therapeutics Inc Fused ring azadecalin glucocorticoid receptor modulators
CA2761255C (en) 2009-05-12 2017-05-09 Corcept Therapeutics, Inc. Solid forms and process for preparing (r)-4a-ethoxymethyl-1-(4-fluoro-phenyl)-6-(4-trifluoromethyl-benzenesulfonyl)-4,4a,5,6,7,8-hexahydro-1h,1,2,6-triaza-cyclopenta[b]naphthalene
US8710035B2 (en) 2010-03-24 2014-04-29 The University Of Chicago Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
TW201247610A (en) 2011-03-15 2012-12-01 Abbott Lab Nuclear hormone receptor modulators
WO2013039916A1 (en) * 2011-09-12 2013-03-21 The United States Of America, Represented By The Secretary, Dept. Of Health And Human Services Compositions for and methods of treatment and enhanced detection of non-pituitary tumors
WO2013052652A1 (en) 2011-10-04 2013-04-11 Erard Gilles Methods and systems for identifying and treating anti-progestin sensitive tumors
WO2013169971A1 (en) 2012-05-10 2013-11-14 Bristol-Myers Squibb Company Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
PL3851107T3 (pl) * 2012-05-25 2023-03-06 Corcept Therapeutics Incorporated Modulatory receptorów glukokortykoidowych typu azadekaliny skondensowanej z heteroaryloketonem
US8859774B2 (en) * 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
PT3889181T (pt) * 2012-09-07 2024-05-29 Regeneron Pharma Um anticorpo antagonista de il-4r para utilização no tratamento da dermatite atópica por administração
TWI697334B (zh) * 2013-06-04 2020-07-01 美商再生元醫藥公司 藉由投與ｉｌ-４ｒ抑制劑以治療過敏及增強過敏原-特異之免疫療法的方法
WO2015061752A1 (en) * 2013-10-25 2015-04-30 Pharmacyclics, Inc. Treatment using bruton's tyrosine kinase inhibitors and immunotherapy
US11413332B2 (en) * 2013-11-11 2022-08-16 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
US20160299146A1 (en) * 2013-11-20 2016-10-13 Dana-Farber Cancer Institute, Inc. Kynurenine Pathway Biomarkers Predictive of Anti-Immune Checkpoint Inhibitor Response
EP3074011B1 (en) * 2013-11-25 2019-07-24 Corcept Therapeutics Incorporated Octahydro fused azadecalin glucocorticoid receptor modulators
CN106456724A (zh) * 2013-12-20 2017-02-22 博德研究所 使用新抗原疫苗的联合疗法
LT3087071T (lt) 2013-12-24 2018-11-12 Bristol-Myers Squibb Company Tricikliniai junginiai kaip priešvėžiniai agentai
AU2015265871B2 (en) * 2014-05-30 2020-01-23 Ventana Medical Systems, Inc. Multiplex assay for improved scoring of tumor tissues stained for PD-L1
SI3805222T1 (sl) 2015-01-30 2025-04-30 Oncoceutics, Inc. Derivati 7-benzil-4-(2-metilbenzil)-2,4,6,7,8,9-heksahidroimidazo[1,2-a] pirido[3,4-e]pirimidin-5(1H)-ona, njihove soli in njihova uporaba v terapiji
WO2016141365A1 (en) * 2015-03-05 2016-09-09 Abraxis Bioscience, Llc Method for treating cancer based on level of glucocorticoid receptor
MX390517B (es) 2016-03-01 2025-03-20 Corcept Therapeutics Inc Uso de moduladores del receptor de glucocorticoides para potenciar inhibidores de puntos de regulacion.
EP3612181A4 (en) 2017-04-21 2021-01-06 Epizyme, Inc. Combination therapies with ehmt2 inhibitors

Also Published As

Publication number Publication date
CN109071537A (zh) 2018-12-21
US12171760B2 (en) 2024-12-24
CA3015218A1 (en) 2017-09-08
JP2019507159A (ja) 2019-03-14
JP2025028214A (ja) 2025-02-28
CN109071537B (zh) 2024-07-05
JP2023060061A (ja) 2023-04-27
MX390517B (es) 2025-03-20
PH12018501848A1 (en) 2019-01-28
PH12018501848B1 (en) 2024-02-23
JP2019023228A (ja) 2019-02-14
EP3423453A1 (en) 2019-01-09
WO2017151613A1 (en) 2017-09-08
KR20180116372A (ko) 2018-10-24
CL2018002467A1 (es) 2018-11-23
AU2017228329A1 (en) 2018-09-06
JP6847120B2 (ja) 2021-03-24
US20190083486A1 (en) 2019-03-21
IL261502A (en) 2018-10-31
EP3423453A4 (en) 2019-11-06
SG11201807421TA (en) 2018-09-27
IL261502B2 (en) 2023-03-01
BR112018067330A2 (pt) 2019-01-22
IL297201A (en) 2022-12-01
US20250073224A1 (en) 2025-03-06
US10980797B2 (en) 2021-04-20
KR102845317B1 (ko) 2025-08-13
IL261502B (en) 2022-11-01
US20210205294A1 (en) 2021-07-08
NZ745540A (en) 2025-03-28
AU2017228329B2 (en) 2021-03-11
ZA201805787B (en) 2020-05-27

Similar Documents

Publication Publication Date Title
MX2018010564A (es) Uso de moduladores del receptor de glucocorticoides para potenciar inhibidores de puntos de regulacion.
MX2023004593A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
CL2019002314A1 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr).
ECSP19055169A (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
MX2018005528A (es) Inhibidores de ret.
CL2019000230A1 (es) Composiciones y métodos de inhibición del masp-3 para el tratamiento de diversas enfermedades y trastornos.
ECSP19055179A (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
CL2016003398A1 (es) Compuestos de heteroarilo útiles como inhibidores de enzima activadora de sumo.
MX381046B (es) Anticuerpos anti-csf1r e inhibidores de pd-1/pd-l1, y usos de los mismos para el tratamiento de cáncer remisión a las solicitudes relacionadas.
MX2018013593A (es) Terapias combinadas de inhibidores de hdac e inhibidores de pd-l1.
CL2017001046A1 (es) Inhibidoes del bromodominio
MX2017010773A (es) Inhibidores de muerte programada 1 (pd-19)/ligando de muerte progamada 1 (pd-l1) para el tratamiento de cancer.
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
CR20150664A (es) Moduladores de los receptores de estrógeno y sus usos
MX2018015352A (es) Subtipos de receptores y compuestos retinoides y rexinoides de funcion selectiva combinados con moduladores inmunitarios para inmunoterapia contra el cancer.
CL2015003200A1 (es) Potenciador de inhibidores del homólogo de zeste
CL2015002151A1 (es) Biaril amide compuestos como inhibidores de quinasa
MX2017016041A (es) Metodos para usar activadores de piruvato cinasa.
CL2018001252A1 (es) Métodos para tratar esclerosis múltiple usando compuestos de pirimidina y piridina con actividad inhibidora de tirosina cinasa de bruton
CL2017002170A1 (es) Desacetoxitubulisina h y análogos de esta.
UY35687A (es) Inhibidores de rorc2 y sus métodos de uso
MX2019005833A (es) Administracion transdermica de agentes grandes.
MX2019004030A (es) Inhibidores del receptor de glucocorticoides.
MX2019006694A (es) Oxabicicloheptanos para la modulacion de la respuesta inmunitaria.
CO2017002356A2 (es) Métodos para tratar la depresión usando moduladores de nmda